Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interviews

Set Alert for Interviews

A selection of in-depth interviews and profiles of policymakers and industry executives.

Orchard On The Trials, Tribulations And Triumphs Of Gene Therapy HTA

Convincing payers to fund a $3m therapy is no mean feat, even for innovations with curative potential. Orchard Therapeutics, a company with much experience in this field, tells the Pink Sheet why it values open dialogues, and outlines how health technology assessment methods could be improved.

Companies Cost Effectiveness

As New Tech Emerges For Early Research, FDA Chief Scientist Says Diversity Must Start In Preclinical Development

In a Pink Sheet interview Chief Scientist Bumpus discusses need to move diversity conversation up further in the pipeline. Better ‘organs on a chip’ should help.

Leadership Diversity & Inclusion

EU Picks Up The Pace On Home Delivery Of Study Drugs

As drug companies get “really organized” about incorporating patient-centric elements in their clinical trials, a senior executive at a global courier company says the time is ripe for the EU to produce harmonized guidance on easing a clinical trial participant’s access to the study drug.

Europe Clinical Trials

Japan Takes New Steps To Build On Real-World Data Foundations

As Japan widens its window for the use of real-world data to support drug development though revision of the Next Generation Medical Infrastructure Act, the pharma industry is hoping for more regular inclusion in regulatory filings. A dedicated group within the PMDA shares its views on how the area is developing and practical measures being taken to drive RWD adoption.

Japan Regulation

Impasse At US FDA Could Mean Stealth Abandons Barth Syndrome Treatment

In an interview with the Pink Sheet, Stealth’s CEO says she is not confident the company could design a clinical trial in the rare disease that would meet the FDA’s expectations.

Rare Diseases Drug Review

How AI Can Help Reduce Vaccine R&D From A Year To ‘A Matter Of Weeks’

From rapidly identifying antigenic targets to automating clinical trials, AI has an important role to play in cutting vaccine development time down to 100 days, says Melanie Saville, executive director of R&D at CEPI.

Europe International

US FDA’s New Generics Chief: We Need More Flexibility For Complex Products

Iilun Murphy said Hatch-Waxman was written with immediate-release oral drugs in mind, not the complex generics becoming more popular today. The agency is evaluating the issue.

Generic Drugs Leadership

Should Pharma Firms Cover CDx Costs For Precision Cancer Drugs?

Significant financial reward awaits drugmakers that invest more in companion diagnostics during the development and marketing of precision cancer drugs, says Peter Keeling, CEO of Diaceutics – but Novartis warns that relying on pharma firms to fund these tests is unsustainable.

Europe International

Rare Diseases: European Market Access ‘Better Organized’ Than US, Says Rhythm

Rhythm is working with country-level authorities and centers of excellence in Europe to gain reimbursement and access for its obesity treatment Imcivree.

Europe EU

New Public Citizen Health Lead To Keep Banging Drum On Stronger Benefit-Risk Ratios

Robet Steinbrook, the third director of the 50-year-old health group, plans to stay true to the organization’s long-held mission of holding FDA drug approvals to high standards, pushing for stronger evidence of benefit, more attention to safety, and advisory committee votes.

Drug Safety Drug Approval Standards

Stephen Hahn On Risk-Taking, Moving To ‘Friction,’ And What Industry Can Learn From The FDA

The former US FDA commissioner turned venture CEO believes the biopharmaceutical industry can cure many of society’s ills, but firms need to talk to the agency more.

Leadership Politics

Different, But Not Poles Apart: Running Decentralized Clinical Trials In EU & US

This second segment of a two-part article on a regional comparison of EU and US approaches to decentralized clinical trials highlights the differences between the two regions relating to the more practical aspects of setting up and running such studies.

Clinical Trials Guidance Documents

Principles-Based vs Prescriptive: How US & EU Compare In Their Approach To Decentralized Trials

In this regional comparison, regulatory experts at a US-based decentralized clinical trials (DCT) firm discuss their views on how the FDA’s draft DCT guideline compares with the pan-EU recommendation paper on this topic. This first segment of a two-part article dwells on the thinking behind why US and EU regulators tend to go down different paths. 

Clinical Trials Guidance Documents

Vistagen Getting 'Back On Offense’ After US FDA Okays Endpoint For Its Social Anxiety Drug

CEO Shawn Singh discusses path forward for fasedienol (PH94B) using the classic LSAS primary endpoint in next clinical trial. Pherine nasal spray candidate failed to meet the primary endpoint (the patient-reported SUDS) in its first pivotal Phase III study, whose design was constrained by the Covid pandemic.

Clinical Trials FDA

BIO Worried CMS’ Alzheimer’s Coverage Is ‘Trial Balloon’ For Lower Accelerated Approval Reimbursement

In a Pink Sheet interview, BIO Chief Advocacy Officer Nick Shipley raised concerns that Medicare’s Alzheimer’s coverage decision is indicative of a broader agency view on accelerated approval that could limit drug reimbursement in both the public and private sector. 

Pricing Debate Reimbursement

GSK’s Walmsley On US v. EU COVID-Flu Combos, RSV Branding, And Investing In Infectious Disease

COVID vaccine makers already licensed in the US will have a leg up on in the combination respiratory vaccine space since aspiring new entrants like GSK will have to do efficacy work to get FDA approval. CEO Walmsley offers insight into the company’s vaccine strategy.

Vaccines Regulation
UsernamePublicRestriction

Register